期刊文献+

水合肼还原制备3-氨基-2-[(2'-氰基联苯-4-基)甲基]氨基-苯甲酸乙酯的工艺研究

Synthesis technology of ethyl 3-amino-2-[(2'-cyanobiphenyl-4-yl) methylamino]benzoate by hydrazine hydrate reduction method
原文传递
导出
摘要 目的研究3-氨基-2-[(2'-氰基联苯-4-基)甲基]氨基-苯甲酸乙酯的最优合成工艺。方法以2-[(2'-氰基联苯-4-基)-甲基]氨基-3-硝基苯甲酸乙酯为原料,水合肼为还原剂,Pb/C为催化剂,还原制得。结果原料与还原剂的最佳物质的量比为1.92:1,催化剂Pd/C为1.2g,反应温度为75℃,反应时间2h的最优条件下,收率为92.0%。结论本合成工艺稳定,条件温和,产率高,适合3-氨基-2-[(2'-氰基联苯-4-基)甲基]氨基-苯甲酸乙酯的工业化生产。 Objective To optimize the synthesis technology of ethyl 3-amino-2-[(2'-cyanobiphenyl-4-yl) methylamino] benzoate. Methods Using ethyl 2-[(2'-cyanobiphenyl-4-yl) methylamino]-3-nitrobenzoate as starting material, hydrazine hydrate as reducing agent, and Pb/C as catalyst, ethyl 3-amino-2-[(2'-cyanobiphenyl-4-yl) methylamino] benzoate was obtained. Results Under the optimum conditions: molar ratio of raw material-reducing agent was 1.92:1, the quantity of catalyst Pb/C was 1.2 g, and at 75 ℃ for 2 h, the yield reached 92.0%. Conclusion The synthesis technology of ethyl 3-amino-2-[(2'-cyanobiphenyl-4-yl) methylamino] benzoate is stable, simple, high yield, and could be applied to industry production.
出处 《现代药物与临床》 CAS 2012年第6期555-557,共3页 Drugs & Clinic
关键词 3-氨基-2-[(2'-氰基联苯-4-基)甲基]氨基-苯甲酸乙酯 水合肼 PB C 还原 ethyl 3-amino-2-[(2'-cyanobiphenyl-4-yl) methylamino] benzoate hydrazine hydrate Pb/C reduction
  • 相关文献

参考文献10

  • 1王书梅.坎地沙坦酯的临床研究[J].中外医疗,2008,27(16):59-60. 被引量:6
  • 2陈仲强,陈虹.现代药物的制备与合成[M].第2卷.北京:化学工业出版社,2007.
  • 3Benz M, Prins R. Kinetics of the reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst [J]. Appl Catal A: Gen, 1999, 183(2): 325-333.
  • 4Kumbhar P S, Sanchez-Valente J, Millet J M M, et al. Mg-Fe hydrotalcite as a catalyst for the reduction of aromatic nitro compounds with hydrazine hydrate [J]. J Catal, 2000, 191(2): 467-473.
  • 5Shakhnes A K, Vorob'ev S S, Shevelev S A. Selective reduction of one, two, or three nitro groups in 1,3,5- trinitrobenzene with hydrazine hydrate [J]. Russ Chem Bull, 2006, 55(5): 938-939.
  • 6Shevelev S A, Shakhnes A K, Ugrak B I, et al. High selective one-step synthesis of 2-amino-4,6-dinitrotoluene and 2,6-diamino-4-nitro-toluene from 2,4,6-trinitrotoluene [J]. Synth Commun, 2001, 31(17): 2557-2561.
  • 7Lauwiner M, Roth R, Rys E Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide/hydroxide catalyst. III. The selective reduction of nitro groups in aromatic azo compounds [J]. Appl CatalA: Gen, 1999, 177(1): 9-14.
  • 8姜小莹,黄建华,李建平.水合肼对芳酰基芳基偶氮化合物的选择性还原[J].化学研究与应用,2010,22(4):511-513. 被引量:4
  • 9闻韧.药物合成化学[M].第2版.北京:化学工业出版社,2003.
  • 10武田药品工业株式会社.苯并咪唑衍生物及其制备和用途[P].CN91102569.3.1991-11-06.

二级参考文献20

  • 1张学景,邹永,魏文,熊晓云.3,5-二硝基苯甲酸甲酯与水合肼的反应研究[J].化学试剂,2005,27(3):169-170. 被引量:2
  • 2蔡可迎,丁明洁,宗志敏,魏贤勇.水中水合肼还原芳香族硝基化合物的研究[J].化学世界,2007,48(4):232-234. 被引量:27
  • 3都本洁.第1讲 心力衰竭的近代观点(4)[J].临床荟萃,1997,12(4):187-191. 被引量:4
  • 4都本洁.第1讲 心力衰竭的近代观点(3)[J].临床荟萃,1997,12(3):141-144. 被引量:1
  • 5[1]Unger T.Pharmacology of AT1-receptor blockers[J].Blood Press,2001,(3):5.
  • 6[2]Pharmaceutical research division.Japan:Takeda Chemical Industries:532~8686.
  • 7[3]Pollek DM,Morsing P.Effects of candesartan cilexetil in patients with systemic hypertension.Candesartan cilexetil study investigators[J].Am J Cardiol,1998,82(8):961.
  • 8[4]Sever PS,DahifB,PoulterNR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations,in the Anglo-Scandinavian cardiac Qutcomes Trial-lipid lowering Arm(ASCOT2LLA):a multicentre ran domized controlled trial[J].Lancet,2003,361:1149~1158.
  • 9[5]Rieger GA,Bouzo H,Petz P,et al.Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil.Symptom,Tolerability,Response to Exercise Tria of Candesartan cilexetil in Heart Failure(STRETCH)Investigators[J].Circulation,1999,100(22):2224~2230.
  • 10[8]Yusuf S,Pfeffer MA,Swedberg K,et al.Effects of can desartan in patients with chronic heart failure and pre-served left ventricular ejection fraction:the CHARM-Preserved Trial[J].Lancet,2003,361 (9386):777~781.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部